Appetite Regulation and Mycoprotein (mycoprotein)

The purpose of this study is to investigate the effect of eating various levels of mycoprotein (Quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.

Study Overview

• Status: Completed
• Conditions: Energy Intake; Appetite
• Intervention / Treatment: Dietary supplement: mycoprotein; Dietary supplement: control protein

Detailed Description

Owing to its relatively high protein and fibre content, mycoprotein presents an attractive food product to improve appetite regulation and postprandial glycaemic and insulin responses in overweight and obese individuals at risk of developing T2DM

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, W12 0NN
    • Imperial College NIHR CRF

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males and females between the ages of 18 and 65
• body mass index (BMI) 25-32kg/m2
• Weight stable over the past 6 months
• No known major illness or eating disorder nor on any medication that may impact on appetite or hormone levels.
• No paracetamol or other analgesic in the previous 48 hours
• A score of <2.5 in the Dutch Eating Behaviour Questionnaire (DEBQ)
• A score of <2 in the SCOFF questionnaire

Exclusion Criteria:

• Persons outside the age and BMI ranges stated above
• Pregnant and lactating women
• Weight variation of greater than 5% in the last 6 months
• Any diagnosed major illness
• Any paracetamol or analgesic intake in the last 48 hours
• Diagnosed eating disorder
• Allergy to mycoprotein or mushrooms
• Regular consumption of Quorn products
• Dislike of any of the test foods or drinks
• A score of >2.5 in the Dutch Eating Behaviour questionnaire
• A score of 2 or more in the SCOFF questionaire

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: mycoprotein; 3 levels of mycoprotein will be consumed	Dietary supplement: mycoprotein
Active Comparator: control protein; 3 levels of a control protein will be consumed	Dietary supplement: control protein

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Energy intake at ad-libitum meal	Energy intake will be assessed during an ad-libitum meal at 180 minutes at the end of each study visit. Participants will be offered a meal in excess and asked to eat until they feel comfortably full. The meal will be weighed before and after consumption and energy intake will be calculated from the manufacturer's reported nutritional composition.	upon completion of all participants, expected timeframe: 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glucagon-like peptide-1 (GLP-1)	Plasma glucagon-like peptide-1 (GLP-1) concentrations will be measured by radioimmunoassay (RIA) at the end of the study	upon completion of all participants, expected at 2 years
peptide tyrosine-tyrosine (PYY) levels	Plasma peptide tyrosine-tyrosine (PYY) concentrations will be measured by radioimmunoassay (RIA) at the end of the study	upon completion of all participants, expected at 2 years

Collaborators and Investigators

• Sponsor: Imperial College London
• Investigators: Principal Investigator: Gary Frost, Imperial College London

Publications and helpful links

General Publications

• Bottin JH, Swann JR, Cropp E, Chambers ES, Ford HE, Ghatei MA, Frost GS. Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial. Br J Nutr. 2016 Jul;116(2):360-74. doi: 10.1017/S0007114516001872. Epub 2016 May 20.

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2010
• Primary Completion (Actual): October 1, 2012
• Study Completion (Actual): October 1, 2012

Study Registration Dates

• First Submitted: January 22, 2014
• First Submitted That Met QC Criteria: January 31, 2014
• First Posted (Estimate): February 3, 2014

Study Record Updates

• Last Update Posted (Actual): October 16, 2019
• Last Update Submitted That Met QC Criteria: October 14, 2019
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Keywords: obesity; overweight; appetite; energy intake; gut hormones
• Other Study ID Numbers: CRO1332

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No